Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Document › Details

InSphero AG. (12/14/23). "Press Release: InSphero Strengthens Its Executive Team by Appointing Paul Clémençon, MBA as Chief Business Officer". Zürich.

Organisation Organisation InSphero AG
  Group InSphero (Group)
Products Product 3D cell culture technology (organoid technology)
  Product 2 organ-on-a-chip technology
Persons Person Clémençon, Paul (InSphero 202312– CBO joined 2022 as Head of Business Development)
  Person 2 Lichtenberg, Jan (InSphero 201401 CEO + Co-founder)

InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team.

Since joining the company in 2022 as the Head of Business Development, Paul has been an integral part of the team, leading the sales strategy with exemplary dedication and acumen. His strategic insights acquired over many years of experience in the biotechnology sector and his unwavering commitment to InSphero’s mission have been pivotal in driving the company's growth in 2023, alongside the successful completion of a funding round and creating key business partnerships.

Commenting on the appointment, Dr. Jan Lichtenberg, CEO and Co-founder of InSphero said, “It is with great pleasure that I announce Paul’s promotion from Head of Business Development to Chief Business Officer. His extensive experience in sales, product management, and marketing, coupled with his profound understanding of the biotech sector, makes him the ideal leader to guide InSphero’s business strategy through the next phase of growth. Paul’s vision for InSphero aligns perfectly with our goal of leading at the forefront of 3D cell-based assays and organ-on-chip systems, and his leadership will be invaluable in enhancing our market presence and customer relations.”

As part of the Executive Team, Paul Clémençon will lead the company's strategic initiatives and overall business development, strengthening InSphero’s positioning as the pioneer and the Model of Excellence™ for reliable, scalable, and reproducible 3D in vitro research. "Being part of a transformational journey of an innovative and successful biotech company with great products and services to the pharmaceutical, biotech, and academic markets has been a great experience", said Paul. "Along with a brilliant and innovative team at InSphero, it is an honor to drive the company’s ambitious strategy to be the leading company in supporting the creation of safer drugs and addressing unmet medical needs”.

# # # #

About InSphero

InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective and safe therapies to get to the clinic faster due to our superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer engagement, commitment to innovation, and the model of excellence.

Learn more at  and follow the company on LinkedIn.

Media Contacts

Rositsa Hadzhipetrova

Record changed: 2024-01-20


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for InSphero (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px

» top